| 1 |
35235141 | A patent review on efficient strategies for the total synthesis of pazopanib, regorafenib and lenvatinib as novel anti-angiogenesis receptor tyrosine kinase inhibitors for cancer therapy. | 2022 Mar 2 |
2 |
| 2 |
32052681 | Regorafenib sensitizes human breast cancer cells to radiation by inhibiting multiple kinases and inducing DNA damage. | 2021 |
1 |
| 3 |
31608707 | The role of PIGF blockade in the treatment of colorectal cancer: overcoming the pitfalls. | 2020 Jan |
1 |
| 4 |
32207565 | Initial in vivo testing of a multitarget kinase inhibitor, regorafenib, by the Pediatric Preclinical Testing Consortium. | 2020 Jun |
1 |
| 5 |
32457362 | Regorafenib is effective against neuroblastoma in vitro and in vivo and inhibits the RAS/MAPK, PI3K/Akt/mTOR and Fos/Jun pathways. | 2020 Aug |
1 |
| 6 |
32660121 | Regorafenib Regulates AD Pathology, Neuroinflammation, and Dendritic Spinogenesis in Cells and a Mouse Model of AD. | 2020 Jul 9 |
2 |
| 7 |
30940655 | Regorafenib Promotes Antitumor Immunity via Inhibiting PD-L1 and IDO1 Expression in Melanoma. | 2019 Jul 15 |
1 |
| 8 |
29359239 | The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myeloma. | 2018 May |
1 |
| 9 |
30069758 | Regorafenib. | 2018 |
2 |
| 10 |
29262623 | Small molecule inhibitor regorafenib inhibits RET signaling in neuroblastoma cells and effectively suppresses tumor growth in vivo. | 2017 Nov 28 |
4 |
| 11 |
26419617 | Involvement of Notch-1 in Resistance to Regorafenib in Colon Cancer Cells. | 2016 May |
1 |
| 12 |
26651387 | The safety of regorafenib for the treatment of gastrointestinal stromal tumors. | 2016 Jan |
1 |
| 13 |
26865419 | Multikinase inhibitor regorafenib inhibits the growth and metastasis of colon cancer with abundant stroma. | 2016 May |
1 |
| 14 |
26327919 | Management of regorafenib-related toxicities: a review. | 2015 Sep |
2 |
| 15 |
24559322 | Regorafenib in metastatic colorectal cancer. | 2014 Mar |
1 |
| 16 |
24744988 | Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) Non-Small Cell Lung Cancer Globally? | 2014 |
1 |
| 17 |
24756792 | Regorafenib. | 2014 |
2 |
| 18 |
23610528 | Critical appraisal of the use of regorafenib in the management of colorectal cancer. | 2013 |
1 |
| 19 |
22421192 | A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. | 2012 May 1 |
1 |
| 20 |
22577890 | Regorafenib for cancer. | 2012 Jun |
2 |
| 21 |
21170960 | Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. | 2011 Jul 1 |
1 |